22:39 , Jun 5, 2019 |  BC Extra  |  Company News

BMS brings in Novartis exec to round out post Celgene acquisition team

With the hire of Novartis’ Samit Hirawat, Bristol-Myers gains some of the R&D chops it needs to become less reliant on its blockbuster checkpoint inhibitors. As it nears the close of its acquisition of Celgene...
17:38 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
23:43 , Jan 14, 2019 |  BC Extra  |  Politics & Policy

House begins campaign to publicize and politicize drug pricing

Requests for pricing and cost information sent Monday by the House Oversight and Reform Committee to a dozen biopharma companies mark the start of what is certain to be a sustained campaign by House Democrats...
19:18 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

Private sharing

A new cryptographic computational protocol from the Massachusetts Institute of Technology will allow drug companies to pool data for predictive modeling of drug-target interactions without revealing the underlying drugs, targets or observed interactions. The method...
23:10 , Oct 26, 2018 |  BC Extra  |  Politics & Policy

China essential drug list includes newly approved HCV therapy

China released its updated essential drug list , reflecting over 100 newly added drugs across multiple categories, including cancer and pediatric drugs. Cancer drugs Iressa gefitinib, MabThera rituximab, Gleevac imatinib and Herceptin trastuzumab were among...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastrointestinal cancer Cell culture and mouse studies identified a quinazoline-based compound that could help treat c-Kit- and PDGFR-mutant gastrointestinal stromal tumors (GISTs). Chemical synthesis of phenoxyquinazoline- and quinolone-based PDGFRA inhibitors followed by testing in...
19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
15:24 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Deciphera reports updated Phase I data for DCC-2618 in GIST

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase...
20:12 , Jun 4, 2018 |  BC Extra  |  Clinical News

Deciphera rises on GIST response data, proposes follow-on

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) added $12.40 (48%) to $38.31 on Monday after reporting updated data from heavily pretreated patients with gastrointestinal stromal tumors who received the company's DCC-2618 in a Phase I trial. The data...
17:57 , May 4, 2018 |  BioCentury  |  Politics, Policy & Law

A Remembrance: An exceptional responder

Jane Reese-Coulbourne was an exceptional responder. In 1990, faced with a diagnosis of advanced breast cancer, she enrolled in a clinical trial at the National Cancer Institute, enduring a grueling regimen of high doses of...